Engineered to deliver the most durable heart valve for patients with severe aortic stenosis - DurAVR™ Transcatheter Heart Valve elevates science and enhances the human life.
Anteris Technologies is a Structural Heart Company committed to discovering, developing, and delivering a pipeline of innovative medical device solutions that aim to improve the health outcomes of patient populations and dramatically improve people's lives.
We drive awareness and adoption of our ADAPT technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.
US FDA grants DurAVR™ THV
approval for Early Feasibility Study (EFS)
November 2022
ASX Announcement
PCR London Valves: Expert Interview
DurAVR THV Impact of Novel Leaflet Design on Hemodynamics and Physiology
Presented by:
Faculty: Bernard Prendergast, MD
Joao Cavalcante, MD, and Chris Meduri, MD
Watch Here
PCR London Valves: Late Breaking Clinical Trial
DurAVR THV First-in-Human Study, 30-day Results
Presented by Chris Meduri, MD
Karolinska University Medical Center, Sweden
View Here
PCR London Valves: Rapid Fire Abstract
DurAVR THV Novel Leaflet Design Restores Aortic Flow and Hemodynamics on Cardiac MRI Analysis
Presented by Pankaj Garg, MD
University of East Anglia, United Kingdom
